Clinicians continue to explore risk factors and apply clinical pathways to prevent the occurrence of an ectopic pregnancy during assisted reproduction technologies treatment. Rombauts et al.
The study included patients who underwent an OI cycle from 2001-2018 using clomiphene citrate (CC) or letrozole. Gonadotropin cycles were excluded. OI cycles were separated into groups based on outcome (ectopic pregnancy (EP) and no EP). EnT was treated as a continuous variable. A sub-analysis was performed treating EnT as a dichotomous variable, thin (<7mm) or not thin (≥7mm). Age, body mass index (BMI), EnT and endometrial pattern (EnP) at time of surge, gravidity, parity, and anti-mullerian hormone level (AMH) were collected. Data were analyzed using t-tests, Chi square analysis, and binary logistic regressions with a general estimate equation (GEE) model with an exchangeable working correlation structure to account for repeated measures.
Results:
A total of 22,956 OI cycles from 11,043 patients were included. Baseline characteristics were similar between cycle outcome groups (Table 1 ). There was a significant difference in the number of CC cycles that resulted in a thin lining (<7mm) compared to letrozole (18.6% vs.
13.4%, p=0.0001). The overall rate of EP in the study was 1.13% (n=259). There was no difference in the rate of EP between CC or letrozole cycles (1.15% vs. 1.07%, p=0.65). 
Conclusions:
In contrast to recent reports that EnT is an independent risk factor for EP in IVF cycles, this study demonstrated that there is no association between EnT and EP in OI cycles. Although CC predisposes a patient to having a thin endometrium, there was no increase in the risk of an EP, as compared to patients exposed to letrozole. Clinicians can be reassured that patients do not have a greater risk of experiencing an EP during OI, even in the presence of a thin endometrial lining. 
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